HCPCS Level II code J9324 denotes the injectable chemotherapy agent pemetrexed (Pemrydi RTU) billed per 10 mg unit. Pemetrexed is a cytotoxic antifolate commonly used in the treatment of certain cancers, and precise coding at the unit level affects billing, inventory management, and clinical cost accounting for infusion services nationwide. Accurate use of J9324 is important for hospitals, outpatient infusion centers, and physician offices that provide chemotherapy.

Key payers included in this national overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the typical sites of service where it is used, and the context needed for claims submission. The publication summarizes how unit-based drug codes like J9324 factor into service lines involving chemotherapy, highlights common billing modifiers (listed separately), and outlines typical operational considerations such as dosing units and documentation requirements.

This analysis supplies benchmarks and policy-relevant context for payers and providers, describes potential areas for coding scrutiny, and presents clinical context to support accurate claim submission and reimbursement workflows. Data not available in the input are noted where applicable.